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Smoking cessation is necessary to reach a higher quality of life, and, for a cancer patient, it represents an important step in
improving the outcome of both prognosis and therapy. Being a cancer patient addicted to nicotine may be a critical situation.
We conducted a survey to monitor how many comprehensive cancer centres in Italy have an outpatient smoker clinic and which
kinds of resources are available. We also inquired about inpatient services oﬀering psychological and pharmacological support
for smoking cessation, reduction, or care of acute nicotine withdrawal symptoms. What we have witnessed is a signiﬁcant gap
between guidelines and services. Oncologists and cancer nurses are overscheduled, with insuﬃcient time to engage in discussion
on a problem that they do not consider directly related to cancer treatment. Furthermore, smoking habits and limited training in
tobacco dependence and treatment act as an important barrier and lead to the undervaluation of smokers’ needs.
1.Introduction
“It is a journey, not a fact”: this redeﬁnition of smoking
cessation by Swartz Woods and Jaen [1] is particularly
signiﬁcant for smokers with a medical diagnosis. In this
approach, every exchange between health system and users
may have an educative impact, and not only on the patient.
Hospitalization is a “teachable moment” [2]a si se v e r y
encounter with health personnel an opportunity to interfere
with the tobacco epidemic, the most preventable of the
world’s health problems and responsible for killing more
people than AIDS, tuberculosis, and malaria put together
[3]. In many illnesses, treating tobacco use and dependence
becomes part of the patient’s care. This is the case for the
treatment of tobacco-related diseases, such as in
(a) most cardiovascular treatments [4],
(b) cancer care [5],
(c) respiratory treatments [6],
(d) every surgical treatment [7],
(e) treatment of patients who need inhaled drugs [8],
(f) prevention of immune system impairment [9, 10].
These considerations should lead to the implementation of
a sound policy in every health organization, but the gap
between theory and clinical practice becomes increasingly
obvious.
In the last few years, Italy has made political progress in
the ﬁeld of tobacco control, such as the 2005 law ensuring
smoke-freeworkplacesandhospitalityvenues.However,11.1
million (21.7%) adults in Italy are still current smokers [11],
and only 375 accredited antismoking centres are operating
[12].2 Journal of Oncology
Table 1: According to Hughes J. R. Nicotine withdrawal symptoms. Eﬀects of abstinence from tobacco: valid symptoms and time course.
Withdrawal Symptoms Peak Duration
Anger/irritability/frustration Within ﬁrst week 2, 4 or more weeks
Anxiety 3 day 2 weeks
Dysphoria (depressed mood and negative aﬀect) 1, 2, 3 weeks 4 weeks
Diﬃculty concentrating 2, 3 days 3, 4 weeks
Impatience 3, 4, or more weeks
Insomnia (sleep fragmentation)
Restlessness 1, 3 days 2, 4 weeks
Whereas the law is being respected in almost all bars
and restaurants, irony wants it that many hospitals are still
laggingbehindinitsimplementation.Wesurveyedthemajor
general hospitals in Milan, the heart of Lombardy’s Health
System and one of the most developed regions in Italy.
Not one of the eight Milan General Hospitals made the
NRT (nicotine replacement therapy) available to clinicians
to deal with smoking cessation or acute nicotine withdrawal
syndrome developed during the inhospital stay. In October
2008, we attended a national Health Promoting Hospitals’
Conference, and were impressed by what was stated on the
situation of tobacco control in three of the eight Milan
General Hospitals. In the ﬁrst hospital, “the No-Smoking
Ban is frequently eluded not only in places like coﬀee
break areas, bathrooms, locker rooms, oﬃces, but also in
places frequented by patients like examination rooms, the
inﬁrmary and recovery rooms.” This study was signed by
the Medical and Surveillance Services and by the Quality
Control Service. In the second hospital, the study conducted
by the Pneumology Rehabilitation Services showed that
45% of nonsmoker employees are exposed to second-hand
smoke during working hours. In the third general hospital,
another study signed by the Pneumology Medical Board
indicated that non-smokers exposed to second-hand smoke
in hospitals accounted for 83% for men and 88.4% for
women [13].
The cancer “setting” might be a good chance to imple-
ment the smoking cessation guidelines, considering that
23.9% of all cancer deaths (33.4% men and 9.6% women)
is due to smoking habits [14].
Among hospitalized cancer patients, smokers constitute
about 24.5% of the total ﬁgure and former smokers about
48.2% [15].
Smoking cessation is an important part of cancer treat-
ment.Diﬀerentstudies indicate thatthesmoking habitinﬂu-
ences the outcome of surgical intervention [16], chemother-
apy[17,18],radiotherapy[19],andbiologicaltherapies[20].
Smoking cessation is also part of the treatment in the
following conditions: lung cancer [21], breast reconstruction
using the free TRAM ﬂap [22], liver transplant [23, 24],
colorectal surgery [25], and bone marrow transplant [26].
Evidence-based treatments of smoking habit in oncolog-
ical patients include nicotine replacement therapies, bupro-
pion, varenicline, and behavioural counselling provided
individually, in groups, or by telephone [27–29]. However,
clinical practice in Italian cancer departments is still far from
such a standard.
In the year 2000, at the National Cancer Institute of
Milan, we initiated a smoke-free campaign addressed to
patients, visitors, and health personnel. The Institute became
a member of the network of smoke-free hospitals, and, since
2003, an antismoking centre has been operating with an
average of 350 smokers treated each year. We are at present
providing pharmacological and psychological support as
an inpatient service to take care of hospitalized smokers.
Our pharmacy oﬀers nicotine replacement therapy (NRT),
bupropion, and varenicline for smoking cessation and treat-
ment of inpatients’ severe acute nicotine withdrawal syn-
drome. We have summarized, in Table 1, the acute nicotine
withdrawal symptoms. Diﬀerential diagnosis of this syn-
drome is made by trained ward clinicians or by neurologists
who call upon the intervention of the inpatient anti-
smoking service. In Table 2, we report the last 11 smoker
patientsdiagnosedwiththissyndromeandtreatedwithNRT.
This kind of therapy usually resolves patients’ symptoms
within 24 hours.
However, our services are merely a drop in the ocean:
Italy has 11 million smokers, and a considerable part of the
population (approximately 4% or 2.250.000 people, in 2006)
lives with a prior cancer diagnosis [30].
We carried out a telephone survey to study the Italian
oﬀer of treatment against tobacco use and dependence in 17
cancer centres (CC) belonging to “Alleanza contro il Cancro”
(a government initiative that creates a network amongst the
most important cancer institutes or cancer departments in
general hospitals).
We focussed our survey on the services provided to
smoker outpatients (with or without an oncological illness)
and on the services provided for inpatients with lung or head
and neck cancer. Our ﬁrst step was to make a telephonic
enquiry at the diﬀerent Institution desks, asking for an out-
patient antismoking clinic, and we then contacted the clinic
personnel.
In order to favour the cessation or reduction of smoking,
six of these clinics oﬀer both psychological and pharmaco-
logicalsupportwhileoneonlyoﬀersgrouptherapy.InTables
3, 4,a n d5, we describe the organization and the resources of
the 7 existing outpatient Clinics.
For the second part of the survey, we contacted the head
nurses of the 12 lung cancer wards and of the 11 head and
neck cancer wards.
NRT, bupropion, and varenicline are available for inpa-
tients in only one cancer clinic (Table 5). Among the existing
12 lung cancer wards only one oﬀers psychological andJournal of Oncology 3
Table 2: Characteristics of the last 11 inpatients diagnosed with acute withdrawal symptoms and treated at the National Cancer Institute of
Milan.
Gender Age Disease Setting Symptoms Therapy
M 56 Bladder cancer Surgery Restlessness NRT inhaler
F 42 Breast cancer Reconstructive Dysphoria, insomnia NRT inhaler
M 34 Metastatic sarcoma Palliative Anxiety, restlessness, insomnia NRT patch
F 74 Oropharyngeal cancer Surgery Restlessness NRT patch
F 43 Metastatic ovary cancer Surgery Anxiety, insomnia, diﬃculty concentrating NRT patch, inhaler
M 66 Lung cancer Surgery Anxiety, restlessness NRT patch
F 52 Metastatic breast cancer Chemotherapy Insomnia, restlessness, dysphoria NRT patch, inhaler
M 56 Oropharyngeal cancer Surgery Restlessness, craving NRT patch
M 28 Kidney cancer Palliative Anxiety, insomnia, craving NRT patch, inhaler
M 28 Nose cancer Palliative Restlessness, craving NRT patch, inhaler
M 62 Colon cancer Surgery Anxiety, restlessness, insomnia NRT patch
Table 3: Outpatient clinics’ treatments for tobacco use and depen-
dence.
Yes (%) No (%)
NHS-funded antismoking clinic 5 (29.41) 12 (70.59)
Private antismoking clinic 2 (11.76) 15 (88.24)
Table 4: Outpatient Clinics’ multidisciplinary team.
Yes (%) No (%)
Physician 6 (85.71) 1 (14.29)
Psychologist 7 0
Nurse 2 (28.57) 5 (71.43)
Nutritionist 1 (14.29) 6 (85.71)
Pulmonary physiotherapist 1 (14.29) 6 (85.71)
Table 5: Pharmacological treatments at surgical wards disposal to
support inpatient smoking cessation or to care acute nicotine with-
drawal syndrome in the 17 cancer centres.
Yes (%) No (%)
Availability of NRT, bupropion, and/or
vareniclina at Hospitals’ pharmacy
1 (5.88) 16 (94.12)
Table 6: Treatments of tobacco use and dependence for lung cancer
inpatients in the existing 12 surgical wards.
Yes (%) No (%)
Smoking cessation: pharmacological
support
1 (8.33) 11 (91.67)
Smoking cessation: psychological support 1 (8.33) 11 (91.67)
Acute nicotine withdrawal syndrome care 3 (25) 9 (75)
pharmacological support for patients motivated or com-
pelled to quit smoking in order to undergo treatment and
speciﬁc surgery. Acute withdrawal syndrome is usually not
detected nor treated and not bedridden cancer inpatients
continue to smoke during treatment, including the days
prior and following surgery, with the exception of three
wards (Table 6). In these cases head nurses, able to make
Table 7: Treatments of tobacco use and dependence for head and
neck cancer inpatients in the existing 11 surgical wards.
Yes (%) No (%)
Pharmacological support 1 (9.09) 10 (90.91)
Psychological support 1 (9.09) 10 (90.91)
Acute nicotine withdrawal syndrome care 2 (18.18) 9 (81.82)
ad i ﬀerential diagnosis, remembered the presence of an acute
syndrome among their patients. However, only one ward
had a speciﬁc inpatient service to deal with such a situation.
In one ward, patients have been administered NRT drugs
bought by relatives in pharmacies outside the hospital while
in another ward patients are treated by anaesthetists without
using NRT/bupropion/varenicline.
We observed the same situation in the existing eleven
head and neck cancer wards. Only one ward provides an
inpatienttobacco-usetreatmentserviceandacomprehensive
acute nicotine withdrawal syndrome care. The second ward,
listed in the table, treats the syndrome with NRT drugs
bought by relatives outside the hospital (Table 7).
2. Conclusions
Being a cancer patient addicted to nicotine may be a critical
situation. Oncologists and cancer nurses are overscheduled,
with insuﬃcient time to engage in discussion on a problem
thattheydonotconsiderdirectlyrelatedtocancertreatment.
Health personnel’s smoking habits [31] and limited training
in tobacco dependence and treatment act as an important
barrier to progress and lead to the undervaluation of
smokers’ needs.
What must be recognized is that this kind of care can be
a great opportunity, not only to support, but to empower
smoker cancer patients and to motivate profound changes
in their lifestyle. In the cases of acute nicotine withdrawal
symptoms, assistance can be of great comfort and help
and can further improve relations between patient and
hospital operators. It also works towards permanent results
in smoking cessation and increases compliance with hospital
no-smoking policies [29, 32].4 Journal of Oncology
It is of crucial importance that oncologists of every com-
prehensive cancer centre oﬀer patients, and the whole com-
munity, a service of smoking cessation; this service should be
connected with the national quit line and with the antismok-
ing centres network. They should also advocate for tobacco-
free environments in their patients’ communities and share,
with their colleagues, their experience in dealing with the
tobacco epidemic [33].
The basic needs of smoker cancer patients aﬀect human
rights, and recognizing this is an essential part in creating a
quality approach to cancer care.
With a nonjudgmental and relationship-centred ap-
proach, the aim of the intervention should be to inform and
support smoker cancer patients to identify and reach their
ownhealthgoalsaccordingtotheirownneedsandresources.
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